Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Endocrinology and metabolism indexChapter sections
Role and principlesAssessment and patient selectionBaseline assessmentInterventionsMedicines and treatment safetyTargets, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook10 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Metabolic syndrome and fatty-liver risk

Endocrinology and metabolism · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Jaundice with coagulopathy, ascites with sepsis or pain, haematemesis or melaena, severe confusion, or hypoglycaemia in known or suspected chronic liver disease requires urgent hospital assessment. Hyperglycaemic crisis, acute coronary syndrome and stroke follow their own emergency pathways regardless of a metabolic-syndrome label.

Role and principles

Recognise clustered cardiometabolic risk without diagnostic shorthand, identify metabolic steatotic liver and advanced fibrosis, and treat each modifiable vascular and hepatic driver.

The metabolic-syndrome concept is useful for recognising shared risk but can become a shortcut. A person does not gain or lose cardiovascular risk by crossing one arbitrary waist or triglyceride threshold. Record and treat the actual conditions: hypertension, prediabetes or diabetes, dyslipidaemia, central adiposity, smoking, sleep apnoea and kidney or vascular disease.

Steatotic liver associated with metabolic dysfunction is common in this cluster. Ultrasound may identify fat incidentally but is insensitive to mild steatosis and cannot stage fibrosis reliably. Liver transaminases reflect current cellular leakage, not scar burden; some people with cirrhosis have normal results. Once MASLD is established, a validated non-invasive fibrosis pathway decides who can remain in metabolic follow-up and who needs hepatology.

Treatment prevents both vascular and liver outcomes. Cardiovascular disease is a major cause of morbidity in MASLD, so a statin should not be withheld merely because liver fat is present. Weight loss can improve steatosis and metabolic risk, but interventions must remain nutritionally complete and free from stigma. Specialist pharmacological treatment directed at liver histology is evolving and should be checked against current NICE, licence and commissioning guidance rather than inferred from diabetes or obesity indications.

Assessment and patient selection

Insulin-resistant cluster

Central adiposity, hypertension, raised triglycerides, low HDL, acanthosis nigricans, prediabetes or type 2 diabetes commonly coexist; each component needs measurement and its own treatment threshold.

Incidental steatosis

Increased echogenicity on ultrasound or fat reported on CT is often asymptomatic and should prompt cause, alcohol, medicine and fibrosis assessment rather than an isolated repeat ALT.

Possible advanced fibrosis

Thrombocytopenia, splenomegaly, low albumin, prolonged INR, nodular liver, portal-vein changes or an elevated validated fibrosis test raises concern even when transaminases are normal.

Decompensated cirrhosisRed flag

Ascites, jaundice, variceal bleeding, encephalopathy, sarcopenia or hepatorenal dysfunction indicates advanced disease and requires urgent or expedited hepatology depending on physiological stability.

Competing liver cause

Marked enzyme rise, cholestasis, systemic illness, drug timing, viral risk, autoimmune features or iron overload may indicate another or additional liver disease and needs targeted investigation.

Obstructive sleep apnoea

Snoring, witnessed apnoeas and daytime sleepiness often accompany central metabolic risk; untreated OSA worsens wellbeing and blood pressure and warrants a validated sleep pathway.

Baseline assessment

  1. 01
    Waist, BMI and blood pressureFirst step
    Why
    Document central adiposity and a major treatable vascular component.
    Interpretation and limitations
    Use suitable equipment and confirm hypertension through the NICE pathway; waist-to-height ratio complements BMI below 35 but does not determine liver fibrosis.
  2. 02
    HbA1c or fasting plasma glucose
    Why
    Detect prediabetes, type 2 diabetes or metabolic decompensation.
    Interpretation and limitations
    Treat diabetes according to its own guideline and complication profile; symptoms, ketones or severe hyperglycaemia may require urgent action rather than routine MASLD follow-up.
  3. 03
    Full lipid profile and cardiovascular risk
    Why
    Identify atherogenic cholesterol and triglyceride risk needing independent treatment.
    Interpretation and limitations
    Use non-HDL, LDL where valid and triglycerides with QRISK3 only in appropriate primary prevention; established disease and FH bypass ordinary risk scoring.
  4. 04
    Liver blood panel and full blood count
    Why
    Look for injury, synthetic dysfunction, cholestasis and indirect portal-hypertension clues.
    Interpretation and limitations
    Normal ALT does not rule out MASLD or fibrosis; low platelets, albumin or abnormal INR can be more concerning and need urgent cause-aware assessment.

Interventions

01Metabolic reviewTreat the cluster component by componentFirst stepCentral adiposity or dysglycaemia suggests clustered cardiometabolic risk.+
  1. 1Measure pressure, HbA1c, lipids, adiposity, smoking, sleep and liver context, and ask about cardiovascular symptoms, medicines, alcohol and family history.
  2. 2Use separate NICE thresholds to treat hypertension, diabetes, lipids and obesity, agreeing practical nutrition, activity, sleep and smoking goals without depending on a syndrome label.
  3. 3EscalationSchedule integrated review of all targets and medicine burden, escalating to relevant specialists when vascular, respiratory, renal or liver complications emerge.
02Incidental fatty liverMove from steatosis to fibrosis riskImaging reports fatty liver or MASLD is otherwise diagnosed.+
  1. 1

Medicines and treatment safety

Reduces the major cardiovascular burden associated with metabolic dysfunction and steatotic liver disease.

Atorvastatin for cardiovascular prevention in MASLD

Use the NICE indication-based oral dose, commonly 20 mg once daily for eligible primary prevention or 80 mg once daily for secondary prevention, adjusted for interactions and tolerability.

Fatty liver alone is not a contraindication. Check baseline transaminases and the current BNF; NICE suggests considering cessation if liver enzymes double within three months, while pregnancy and severe active liver disease need specialist review.

May be considered by specialist services for selected adults with advanced fibrotic steatotic liver disease.

Pioglitazone in specialist-selected advanced fibrosis

Use only an endocrinology or hepatology-selected once-daily regimen within the current NICE and diabetes context after discussing uncertain liver benefit and patient-specific risks.

Can cause weight gain, oedema, heart failure, fractures and other adverse effects; review bladder history, pregnancy and liver function. Do not prescribe solely for an incidental fatty ultrasound in primary care.

Targets, monitoring and follow-up

  • Repeat ELF at the NICE interval, generally every three years in adults below the advanced-fibrosis threshold, or sooner when clinical evidence changes through specialist advice.
  • Monitor HbA1c, blood pressure, lipids, renal function, smoking and sleep-apnoea treatment according to each condition's guideline rather than a single annual syndrome panel.
  • After statin initiation or dose change, repeat lipids and liver transaminases at two to three months and interpret enzyme trend in context.
  • Track platelets, albumin, INR, bilirubin, weight and symptoms when fibrosis risk is present; decompensation features override the planned routine interval.
  • Review alcohol quantity and pattern without stigma, offering evidence-based support and revisiting because exposure and metabolic vulnerability can change over time.
  • In cirrhosis, follow the hepatology schedule for ultrasound-based hepatocellular-carcinoma surveillance, variceal assessment, vaccination, nutrition and medicine safety.
  • Assess nutrition and muscle function during substantial weight loss, particularly in older adults or advanced liver disease where sarcopenia worsens outcome.

Special situations

ALT is not a scar gauge

Transaminases can normalise as cirrhosis advances because fewer hepatocytes remain inflamed; fibrosis assessment needs validated markers and clinical context.

Fat and alcohol can coexist

Metabolic risk does not cancel alcohol-related injury, and alcohol use does not make central adiposity irrelevant; quantify both rather than choosing one label.

Cardiovascular care saves livers too

Exercise, diabetes control, blood-pressure care and smoking cessation reduce whole-person risk; avoiding statins because of steatosis may increase the larger immediate hazard.

Fibrosis directs follow-up

Simple fat on imaging does not predict an individual's liver outcome as well as scar burden, which is why the ELF step changes referral and surveillance.

High BMI can hide malnutrition

Cirrhosis, rapid loss or severe dietary restriction can deplete muscle and micronutrients even when weight remains above an obesity threshold.

Common pitfalls

  1. 01

    Using a metabolic-syndrome label instead of treating each measured risk factor.

  2. 02

    Reassuring from normal ALT without fibrosis assessment in diagnosed MASLD.

  3. 03

    Assuming fatty appearance explains every abnormal liver test.

  4. 04

    Withholding indicated statin solely because steatosis is present.

  5. 05

    Using ultrasound to stage fibrosis or exclude early steatosis.

  6. 06

    Ignoring alcohol because a person has obesity or diabetes.

  7. 07

    Failing to repeat low-risk ELF at the recommended interval.

  8. 08

    Pursuing rapid weight loss in cirrhosis without protecting protein intake and muscle.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Endocrinology and metabolismOriginal SBA

Normal ALT with diagnosed MASLD

An adult has imaging-confirmed metabolic steatotic liver disease but normal ALT and AST. What is the most appropriate next fibrosis assessment under NICE guidance?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Endocrinology and metabolism topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG49 MASLD recommendationsDiagnosis, ELF threshold, reassessment and specialist treatment principles.
  • NICE NG238 cardiovascular prevention guidanceRisk assessment, statin treatment and lipid response targets.
  • NICE NG246 obesity management recommendationsPerson-centred behavioural, medicine and surgical weight pathways.
  • British Society of Gastroenterology abnormal liver blood testsCurrent BSG resource URL for aetiology screening and fibrosis pathways; confirm the guideline's review status during the scheduled clinical review.
  • BNF pioglitazone prescribing monographDose, heart-failure, fracture and other medicine cautions.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom

Key points

  • Metabolic syndrome describes central adiposity, dysglycaemia, raised blood pressure and atherogenic lipids clustering through insulin resistance; treat the components rather than relying on the label.
  • NICE now uses metabolic dysfunction-associated steatotic liver disease terminology in NG49, while local records and evidence may still say NAFLD; document what diagnostic criteria were used.
  • MASLD ranges from steatosis through inflammatory injury and fibrosis to cirrhosis and liver cancer; fibrosis stage, not transaminase height, drives liver prognosis.
  • Normal ALT and AST do not exclude steatotic liver or advanced fibrosis, and abnormal tests alone do not establish its cause.
  • Assess alcohol sensitively and quantitatively because metabolic and alcohol-related injury can coexist; do not use body size to dismiss harmful alcohol exposure.
  • An incidental fatty liver on imaging should trigger diabetes, blood pressure, lipid, medication and fibrosis-risk assessment rather than reassurance or automatic hepatology referral.
  • For adults with diagnosed MASLD, NICE recommends enhanced liver fibrosis testing to identify advanced fibrosis rather than using routine liver tests as the fibrosis screen.
05
Ultrasound or existing cross-sectional imaging
Why
Identify steatosis, biliary disease, nodularity, spleen and portal features.
Interpretation and limitations
Ultrasound supports steatosis but does not accurately stage scar and can miss mild fat; a normal study does not close a strong alternative liver differential.
  • 06
    Enhanced liver fibrosis test
    Why
    Assess advanced fibrosis risk after MASLD is diagnosed in adults.
    Interpretation and limitations
    NICE uses 10.51 or above to identify advanced fibrosis for specialist referral; below this threshold repeat testing follows the recommended interval, usually every three years for adults.
  • 07
    Aetiology screen for abnormal liver tests
    Why
    Exclude viral, autoimmune, iron-related and other liver diseases that can coexist.
    Interpretation and limitations
    Select viral serology, immunoglobulins and antibodies, ferritin with transferrin saturation and other tests through the local abnormal-liver-blood pathway; fatty imaging is not an exclusion test.
  • 08
    Specialist elastography or liver assessmentFirst line
    Why
    Refine fibrosis, portal-hypertension and cirrhosis risk after an abnormal first-line test.
    Interpretation and limitations
    Transient elastography thresholds depend on device, cause and pathway; hepatology integrates them with ELF, platelets, imaging and clinical evidence rather than using one number alone.
    • Confirm metabolic context, quantify alcohol, review medicines and investigate competing liver causes based on blood pattern, history and local aetiology screen.
  • 2Assess liver synthetic function and request ELF through the NICE pathway rather than using normal transaminases or ultrasound appearance to exclude advanced disease.
  • 3Refer ELF at least 10.51 or other cirrhosis evidence to hepatology; below threshold, manage metabolic risk and plan repeat fibrosis testing at the recommended interval.
    • 03Advanced diseaseEscalate fibrosis or decompensationEscalationELF, imaging, platelets or clinical features suggest advanced fibrosis or cirrhosis.+
    1. 1Assess urgently for jaundice, bleeding, infection, ascites, encephalopathy and renal dysfunction, admitting decompensated patients through the acute liver pathway.
    2. 2Refer compensated advanced fibrosis to hepatology for elastography, cause confirmation, portal-hypertension and hepatocellular-carcinoma surveillance planning.
    3. 3Continue cardiovascular risk reduction, nutrition, vaccination and alcohol support while avoiding unsafe medicines; cirrhosis does not make vascular prevention irrelevant.
    04Weight interventionImprove metabolic health safelyAdiposity is an agreed modifiable contributor to diabetes, vascular or liver risk.+
    1. 1Ask permission, set functional and metabolic goals and design a nutritionally complete energy-deficit plan with activity adapted to mobility, pain and liver stage.
    2. 2Consider anti-obesity medicine or bariatric referral through current eligibility and commissioning, without claiming a liver indication that the product does not hold.
    3. 3Monitor muscle mass and malnutrition in advanced liver disease, where unsupervised rapid loss can worsen sarcopenia despite a high BMI.
    An ELF score of 10.51 or above indicates advanced fibrosis in the NICE pathway and warrants specialist liver assessment; below threshold requires periodic reassessment.
  • Statins are generally safe and important for vascular risk in MASLD; NICE only considers stopping if transaminases double within three months of starting.
  • Weight management, physical activity, glycaemic care, blood pressure treatment, lipid lowering, sleep-apnoea care and smoking cessation form the core treatment package.
  • People with cirrhosis need hepatology-led variceal, hepatocellular carcinoma, nutrition, vaccination and decompensation surveillance beyond a primary metabolic review.